Lisata Therapeutics(LSTA) - 2024 Q1 - Earnings Call Presentation

Appendix Dose on days 1, 8, 15 every 28 days INTERVENTION Arm (N=20) • Nab-paclitaxel 125 mg/m2 IV • Matching certepetide Placebo IV • Gemcitabine 1000 mg/m2 IV • Matching Placebo certepetide IV 4 hours later • Timing: Enrollment completed December 2023; Earliest possible data 2024 Phase 2b randomized, doubleblind study in mPDAC testing gemcitabine + nab-paclitaxel (SoC) with two certepetide dose regimens or placebo Sponsor/Partner ▪ Qilu Pharmaceutical (funds all development in China) ▪ Primary: AEs, SAEs, ...